세계의 색소 침착 치료 시장 규모는 2024년부터 2030년까지 예측기간에 CAGR 7.31%의 성장이 추정됩니다. 시장은 주로 다양한 색소 침착 치료의 유병률 증가로 상당한 시장 성장을 보이고 있습니다. 또한, 청소년층의 피부과 치료에 대한 지출 증가, 아름다운 외모에 대한 젊은층의 의식 증가 등의 요인이, 결과적으로 색소 침착 치료 시장을 지원합니다. 또한, 다마브레이전 및 레이저와 같은 저침습 접근법에 대한 수요 증가는 향후 몇 년 동안 시장을 밀어올릴 가능성이 높습니다. 마찬가지로, 약물 및 장비의 승인이 증가함에 따라 연구개발 활동이 증가하면 시장에서 색소 침착 치료의 요건이 생깁니다. 따라서 시장은 2024년부터 2030년까지 예측기간 동안 상당한 CAGR로 성장할 것으로 추정됩니다.
색소 침착 치료 시장 역학
색소 침착 치료 시장의 성장에 영향을 미치는 주요 요인 중 하나는 세계의 알비니즘, 간반, 백반, 태양 렌티진, 주근깨 등 다양한 색소 침착 치료의 유병률이 증가하고 있다는 것입니다.
예를 들어, 유엔 보고서(2023)에 따르면 북미와 유럽에서는 1만 7,000명-2만명 중 1명이 어떠한 알비니즘을 가지고 있다고 추정되었습니다.
앞서 언급한 자료에 따르면, 알비니즘의 증상은 사하라 아프리카에서 더 흔하며, 탄자니아에서는 1,400명 중 1명이 고통받는 것으로 추정되며, 짐바브웨나 남부 아프리카의 다른 특정 민족 집단에서는 1,000명 에 1명이라는 높은 유병률이 보고되었습니다.
Global Vitiligo Foundation의 최근 조사에 따르면 2022년 전 세계 7천만 명이 백반에 걸렸습니다.
색소 침착 치료은 근본적인 질병에 대처하기 위해 다양한 외용제, 화학 필링, 동결 요법, 광 및 레이저 치료, 또는 이들 기술의 조합에 의해 치료됩니다. 따라서 세계 다양한 색소 침착 치료의 유병률 증가는 외용약 및 미용 시술 수요를 증가시켜 2022년부터 2028년까지 예측기간에 색소 침착 치료의 전체 시장 성장을 가속할 전망입니다.
마지막으로, 제품의 승인 및 출시 증가와 같은 시장에서의 전략적 발전 증가는 색소 침착 치료 치료 시장의 성장을 더욱 향상시키고 있습니다. 예를 들어, 2022년 7월, Incyte Corporation은 성인과 12세 이상의 소아 환자에서 비분절형 vitiligo의 치료제로 Opzelura(룩소리티닙) 크림 승인을 미국 식품의약국에서 받았습니다.
따라서 위의 요인이 총체적으로 2024년부터 2030년까지 예측기간을 통해 색소 침착 치료 시장 전체를 견인할 것으로 예측됩니다.
그러나 미용시술의 높은 비용 및 숙련된 전문가의 부족 등이 예측기간의 색소 침착 치료 시장의 성장을 멈출 가능성이 있습니다.
색소 침착 치료 시장은 COVID-19 팬데믹 기간에 중간 정도의 영향을 받았습니다. COVID-19의 발생 초기에는 바이러스의 확산을 억제하기 위해 엄격한 봉쇄가 부과되었기 때문에 시장에서는 의료기기와 의약품이 크게 부족했습니다. 또한 색소 침착 환자의 치료는 COVID-19 환자에 비해 우선순위가 낮았기 때문에 병원이나 피부과 클리닉에서의 치료 횟수가 적었습니다. 또한 공급망과 원재료의 혼란으로 인해 특정 치료 제품의 생산이 중단되었습니다. 그러나 전자상거래 플랫폼에서 특정 색소 침착 크림 및 미용액과 같은 색소 침착 치료 제품의 가용성과 함께 시장도 완만한 성장을 보였습니다. 이와 같이 위의 요인이 색소 침착 치료 시장을 궤도에 올린 원인이며 예측기간에도 마찬가지일 것으로 전망됩니다.
색소 침착 치료 시장의 부문 분석
색소 침착 치료 시장의 치료 부문에서는 2023년 코르티코 스테로이드 부문이 큰 수익 점유율을 차지한 것으로 평가되었습니다. 이것은 이 부문와 관련된 다양한 장점과 용도 때문입니다. 또한, 색소 침착 코르티코 스테로이드와 관련된 주요 기업의 다양한 전략적 대책은 예측 기간에 코르티코 스테로이드 시장 성장의 촉진요인이 될 것입니다.
본 보고서에서는 세계의 색소 침착 치료 시장에 대한 조사 분석을 실시하고, 시장 규모 및 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 제공합니다.
Pigmentation Disorder Market By Treatment (Pharmacological Treatment [Corticosteroids, Calcineurin Inhibitors, And Others] And Non-Pharmacological/Cosmetic Treatment [Chemical Peels, Laser Treatment, Phototherapy, And Others]), By Indication (Albinism, Vitiligo, Melasma, Post-Inflammatory Hyperpigmentation (PIH), And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of pigmentation disorder such as albinism, melasma, vitiligo, freckles, and others and increasing demand of minimally invasive approaches for pigmentation treatment such as dermabrasion, laser, and others, across the globe
The global pigmentation disorder market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030. The pigmentation disorder market is witnessing considerable market growth primarily owing to the increasing prevalence of various pigmentation disorders. Further, the growing expenditure by young adults on dermatological treatments along with the surging awareness among youngsters about aesthetic appearance, and other factors will ultimately support the market of pigmentation disorders. Also, increasing demand for minimally invasive approaches such as dermabrasion, and laser among others will likely contribute towards pushing the market of pigmentation disorder in the forthcoming years. Similarly, the increasing research & developmental activities along with the rising drug and device approvals will create a requisite for pigmentation disorder in the market. Therefore, the market for pigmentation disorder is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.
Pigmentation Disorder Market Dynamics:
One of the key factors influencing the growth of the pigmentation disorders market is the increasing prevalence of various pigmentation disorders such as albinism, melasma, vitiligo, solar lentigines, ephelides (freckles), and others, across the globe.
For instance, as per the United Nations report (2023), it was estimated that in North America and Europe 1 in every 17,000 to 20,000 people have some form of albinism.
As per the above-mentioned source, the condition of albinism is much more prevalent in sub-Saharan Africa, with estimates of 1 in 1,400 people being affected in Tanzania and prevalence as high as 1 in 1,000 reported for select populations in Zimbabwe and other specific ethnic groups in Southern Africa.
According to the latest study done by Global Vitiligo Foundation, nearly 70 million people across the world had vitiligo, in 2022.
The pigmentation diseases are treated with various topical medicines, chemical peels, cryotherapy, light or laser therapy, or a combination of these techniques to address the underlying illness. Thus, the increasing prevalence of various pigmentation disorders globally will increase the demand for topical medicines or cosmetic procedures, thereby propelling the overall market growth of pigmentation disorders during the forecast period from 2022 - 2028.
Lastly, the increasing strategic development in the market such as rising product approvals, and launches are further increasing the growth of the pigmentation disorder treatment market. For instance, in July 2022, Incyte Corporation received approval from the United States Food and Drug Administration for Opzelura (ruxolitinib) cream for the treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Therefore, the factors stated above collectively will drive the overall pigmentation disorder market throughout the forecast period from 2024-2030.
However, the high cost of cosmetic procedures, lack of skilled professionals, and others may halt the market growth of pigmentation disorders during the forecast period.
The pigmentation disorder market was moderately impacted during the period of COVID- 19 pandemic. At the onset of the disease, there was a significant shortage of devices and drugs in the market, attributed to the imposition of stringent lockdowns to curb the spread of the virus. Moreover, treatment for patients suffering from pigmentation disorders was not a priority in comparison to the patients that were suffering from coronavirus, resulting in a lesser number of treatment sessions in the hospital or dermatological clinics. Additionally, owing to the disruption in the supply chain and raw materials, the production of certain treatment products was shut down. However, with the availability of certain pigmentation creams, serums, and other pigmentation treating products over the e-commerce platforms, the market witnessed a moderate rise also. Thus, the above factor was responsible for bringing the market of pigmentation disorder back on track and is anticipated to do the same during the forecast period.
Pigmentation Disorder Market Segment Analysis:
Pigmentation Disorder Market by Treatment (Pharmacological Treatment [Corticosteroids, Calcineurin Inhibitors, and Others] and Non-Pharmacological/Cosmetic Treatment [Chemical Peels, Laser Treatment, Phototherapy, and Others]), Indication (Albinism, Vitiligo, Melasma, Post-Inflammatory Hyperpigmentation (PIH), and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the treatment segment of the pigmentation disorder market, the corticosteroids segment is expected to have a significant revenue share in the year 2023. This is owing to the various advantages and applications that are associated with the segment. Further, various strategic steps taken by the key players pertaining to corticosteroids for pigmentation disorders will aid in driving the market of corticosteroids during the forecast period.
The topical corticosteroids (TC) application showed quick amelioration of post-inflammatory hyperpigmentation patches. Moreover, corticosteroid drugs are used for the treatment of various pigmentation diseases such as albinism, melasma, vitiligo, solar lentigines, ephelides (freckles), and others.
Also, corticosteroids may be used with non-pharmacological treatment for fasting the process of pigmentation treatment.
Further, various developmental activities by key players such as acquisitions, launches, partnerships, and others will also increase the demand for corticosteroids in the market. For instance, in July 2022, Ahammune Biosciences collaborated with Veeda Clinical Research Limited for investigating AB1001 as a topical therapy for vitiligo.
Therefore, owing to the above-mentioned factors, the demand for corticosteroids will increase during the forecast period, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global pigmentation disorder market.
North America is expected to dominate the overall Pigmentation Disorder Market:
Among all the regions, North America is expected to dominate the global pigmentation disorder in the year 2023 and is expected to do the same during the forecast period from 2024-2030.
This domination is due to the increasing prevalence of pigmentation disorders, the rising geriatric population prone to pigmentation disorders, and technological advancements in treatment options that will boost the pigmentation disorders Market in North America.
For instance, as per the report, people with albinism worldwide, 2022 in the United States, the prevalence of oculocutaneous albinism type 2 was 1 in 6,500 people, in 2022. The increasing prevalence of albinism will increase the demand for topical drugs and cosmetic procedures employed in the treatment of pigmentation disorder.
Further, the availability of various products by the top market competitors, including Obagi Cosmeceuticals, Alvogen, and AbbVie Inc., and increasing business strategies such as mergers, acquisitions, and product launches to strengthen their market position are all anticipated to fuel the market expansion.
For instance, in February 2020, Eli Lilly acquired Dermira for USD 1.1 billion. This acquisition assists the company to expand its pipeline of dermatology medicines, and others with the addition of lebrikizumab, for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older and QBREXZA, for the topical treatment of primary axillary hyperhidrosis, respectively.
Therefore, the interplay of the aforementioned factors would provide a conducive growth environment for the pigmentation disorder market in North America.
Pigmentation Disorder Market Key Players:
Some of the key market players operating in the pigmentation disorder market include AbbVie Inc., DERMAMED SOLUTIONS, obagi Cosmeceuticals LLC., Incyte Corporation., Pierre Fabre group, GALDERMA LABORATORIES, L.P., Alvogen., SkinCeuticals., Arcutis Biotherapeutics, Inc., Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Dermavant Sciences, Inc., Glenmark Pharmaceuticals, Zerigo Health., Novartis AG, Pfizer Inc., Merz GmbH & Co. KGaA, Viatris Inc., Uniza Healthcare, PCA SKIN, and others.
Recent Developmental Activities in the Pigmentation Disorder Market:
In February 2022, Scientis, an emerging leader in the science of skin discoloration, announces the launch of Cyspera® Intensive System(TM), a new three-product system clinically proven to improve hyperpigmentation such as persistent brown patches and dark spots.
In February 2020, PCA SKIN launches two of its most popular chemical peels. These new launches have been added to its extensive lineup of custom blended peel options. The new trichloroacetic (TCA) peel formulas include PCA SKIN Sensi Peel, for people with sensitive skin, PCA SKIN Ultra Peel which can be used for many other skin types, conditions, and sensitivities, and PCA SKIN MD Peel (CCl3) which is most suitable for resilient skin.
Key Takeaways from the Pigmentation Disorder Market Report Study
Target Audience who can be benefited from this Pigmentation Disorder Market Report Study
Frequently Asked Questions for the Pigmentation Disorder Market:
The pigmentation disorders include a large number of diverse conditions that are usually characterized by altered melanocyte density, melanin concentration, or both and result in altered pigmentation of the skin. Pigmentation disorders are classified as hypopigmentation and hyperpigmentation. In hypopigmentation, the pigment is decreased, whereas, in depigmentation, the pigment is completely lost, leaving white skin.
The global pigmentation disorder market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030.
The pigmentation disorder market is witnessing positive market growth owing to the factors such as the increasing prevalence of pigmentation disorders, growing expenditure on dermatological treatments, surging awareness among youngsters about aesthetic appearance, increasing demand for minimally invasive approaches such as dermabrasion, laser, and other, surging new drug launches and approvals, presence of key players in the market, and others will create an exigency for the pigmentation disorder market.
Some of the key market players operating in the pigmentation disorder market include AbbVie Inc., DERMAMED SOLUTIONS, obagi Cosmeceuticals LLC., Incyte Corporation., Pierre Fabre group, GALDERMA LABORATORIES, L.P., Alvogen., SkinCeuticals., Arcutis Biotherapeutics, Inc., Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Dermavant Sciences, Inc., Glenmark Pharmaceuticals, Zerigo Health., Novartis AG, Pfizer Inc., Merz GmbH & Co. KGaA, Viatris Inc., Uniza Healthcare, PCA SKIN, and others.
Among all the regions, North America is estimated to hold a significant revenue share in the global pigmentation disorder market. This can be ascribed to the due the increasing prevalence of pigmentation disorders, the rising geriatric population prone to pigmentation disorders, advancements in devices and drugs, the rising awareness about skincare, and the presence of key domicile players in the region are the reasons which act as a supportive factor for the North America pigmentation disorder market growth.